Finally, we showed that high LOXL2 expression correlates with poor prognosis in ErbB2-positive breast cancer patients, demonstrating a strong link between LOXL2 and ErbB2 and aggressive cell behavior. Here, ERBB2 is linked to breast carcinoma.